Date: 2013-09-02
Type of information: Nomination
Compound:
Company: Kymab (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 2, 2013, Kymab, a monoclonal antibody biopharmaceutical company, announced the appointment of Dr Christian Groendahl as Chief Executive Officer and Dr David Chiswell, currently non-executive Director of Kymab, as Chairman, to take effect from 16 September 2013. Kymab is using the Kymouse™ transgenic human antibody platform to discover and develop fully human monoclonal antibody drugs. Under the leadership of Dr Groendahl, Dr Chiswell and Dr Allan Bradley, Chief Scientific Officer, Kymab plans to further develop its platform and advance several drug candidates to clinical development stage over the next five years.
Financial terms:
Latest news:
